19 Osteogenesis Imperfecta Clinical Trials in Nashville, TN (2026)

Q: How do I join a clinical trial in Nashville?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Nashville research site will contact you.

Recruiting Osteogenesis Imperfecta Studies in Nashville

NCT07224243Recruiting

Impact of Intraoperative Oxygenation Practices on Patient Outcomes

This multicenter, cluster-randomized, cluster-crossover clinical trial evaluates the impact of three intraoperative FiO2 (Fraction of Inspired Oxygen) oxygenation strategies-lower (FiO₂ 0.21-0.40), in...

Nashville, TN54,000 participantsFrederic T Billings IV

View Study Details

NCT06701214Recruiting

The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository

This study will investigate the association between clonal hematopoiesis and other conditions. Clonal hematopoiesis (CH) refers to the mutations in a person's stem cells which commonly affect people a...

Nashville, TN800 participantsVanderbilt-Ingram Cancer Center

View Study Details

NCT01376024Recruiting

Study on Basal Joint Arthritis Prospective

The data in this prospective registry will be used 1) to define which surgical and nonoperative techniques are most effective at providing pain relief, restoring function, are cost effective, and pati...

Nashville, TN800 participantsColumbia University

View Study Details

NCT06651177Recruiting

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD...

Nashville, TN310 participantsT. John Winhusen, PhD

View Study Details

NCT06292780Recruiting

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need...

Nashville, TN220 participantsRegeneron Pharmaceuticals

View Study Details

NCT06118086Recruiting

Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)...

Nashville, TN125 participantsRemix Therapeutics

View Study Details

NCT06630234Recruiting

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module...

Nashville, TN120 participantsDeciphera Pharmaceuticals, LLC

View Study Details

NCT05142267Recruiting

Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms

The purpose of this study is to see how stress influences the effects of opioid pain medications often used to help relieve back pain. The study will help to learn more about how high stress levels co...

Nashville, TN120 participantsVanderbilt University Medical Center

View Study Details

NCT07081646Recruiting

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis....

Nashville, TN91 participantsAlexion Pharmaceuticals, Inc.

View Study Details

NCT07216443Recruiting

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for ...

Nashville, TN80 participantsOrca Biosystems, Inc.

View Study Details

NCT07062588Recruiting

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo....

Nashville, TN80 participantsAngitia Incorporated Limited

View Study Details

NCT06158854Recruiting

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by c...

Nashville, TN76 participantsAbbVie

View Study Details

NCT02702310Recruiting

Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides

This clinical trial studies low- dose total skin electron therapy in treating patients with stage IB-IIIA mycosis fungoides that has not responded to previous treatment (refractory) or has returned af...

Nashville, TN60 participantsVanderbilt-Ingram Cancer Center

View Study Details

NCT05546580Recruiting

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat ...

Nashville, TN50 participantsOryzon Genomics S.A.

View Study Details

NCT05145816Recruiting

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

The goal of this study is to test the safety of drug, Belantamab Mafodotin, and see what effects (good and bad) it has on people who take it and amyloidosis, and to determine the most effective dose o...

Nashville, TN37 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT06034275Recruiting

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ h...

Nashville, TN36 participantsVincerx Pharma, Inc.

View Study Details

NCT06643884Recruiting

Suprachoroidal Administration in Subjects With Choroidal Metastasis From Breast or Lung Primary Tumors

The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with choroidal metastasis from breast or lung primary tumors....

Nashville, TN24 participantsAura Biosciences

View Study Details

NCT06964269Recruiting

Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease

Single-site, open label pilot study of 20 autoimmune patients diagnosed with dry eye demonstrating via the proparacaine challenge some peripheral corneal pain component. At least 16 patients will rece...

Nashville, TN20 participantsToyos Clinic

View Study Details

NCT07306832Recruiting

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment. This study will assess the adverse even...

Nashville, TN18 participantsAbbVie

View Study Details

About Osteogenesis Imperfecta Clinical Trials in Nashville

Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.

There are currently 19 osteogenesis imperfecta clinical trials recruiting participants in Nashville, TN. These studies are seeking a combined 57,067 participants. Research is being sponsored by Frederic T Billings IV, Vanderbilt-Ingram Cancer Center, Columbia University and 14 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Osteogenesis Imperfecta Clinical Trials in Nashville — FAQ

Are there osteogenesis imperfecta clinical trials in Nashville?

Yes, there are 19 osteogenesis imperfecta clinical trials currently recruiting in Nashville, TN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Nashville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Nashville research site will contact you about next steps.

Are clinical trials in Nashville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Nashville studies also compensate for your time and travel.

What osteogenesis imperfecta treatments are being tested?

The 19 active trials in Nashville are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.

Data updated July 13, 2026 from ClinicalTrials.gov